Alterome Therapeutics, Inc.

Venture capital investment in biopharmaceutical companies ticked higher in the first quarter of 2024. In the second quarter, money is flowing into VC investors and funds focused specifically on the li

April began with a flurry of new venture capital mega-rounds of $100m or more – a $160.5m series C round for Obsidian Therapeutics, Inc. , a $132m series B for Alterome Therapeutics, Inc. and a $12

Emalex Biosciences Inc. significantly expanded on its previous capacity to fund the upcoming Phase III clinical trial of ecopipam in Tourette’s syndrome with a $250m series D financing barely a year

There was a shift in venture capital investment trends during the second half of 2021 related to the poor performance of biopharmaceutical companies that went public last year, Silicon Valley Bank (SV